Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4743405 | 1.00 | FFAR4 (0.38) | FFAR4HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL4742713 | 0.82 | CYP2D6 (0.46) | — | |
| SCHEMBL4742712 | 0.82 | CYP2D6 (0.46) | — | |
| SCHEMBL3625680 | 0.80 | LTA4H (0.52) | — | |
| SCHEMBL5367312 | 0.79 | ALDH1A1 (0.51) | HDAC3HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL3621454 | 0.79 | LTA4H (0.51) | — | |
| Hydrochloric Acid SCHEMBL3621460 | 0.79 | LTA4H (0.51) | — | |
| Hydrochloric Acid SCHEMBL5367308 | 0.78 | ALDH1A1 (0.53) | HDAC3HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL27548705 | 0.78 | ALDH1A1 (0.53) | HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL20379010 | 0.77 | HDAC3 (0.44) | FFAR4HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242174-B2 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120157462-A1 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2012-06-21 | — | — | US | disclosed |
| WO-2008094592-A1 | HYDROXAMIC ACID DERIVATIVES OF ANILINE USEFUL AS THERAPEUTIC AGENTS FOR TREATING ANTHRAX POISONING | PANTHERA BIOPHARNA, LLC (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157462-A1 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | ANTXR2, AGXT, AADAC | FFAR4 2422/4885HDAC3 164/4885HDAC1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.